1
|
Sanders Z, Moffitt BA, Treaster M, Larkins A, Khulordava N, Benjock J, Spencer J, Henrie K, Wurst MJ, Broom A, Tamez N, DeRosa G, Campbell M, Keller E, Powell A, Weinbrenner D, Abenavoli L, Edenfield WJ, Chung K, Boccuto L, Ivankovic D. Effects of Origanum majorana on Breast Cancer Cells: An Alternative to Chemotherapy? Metabolites 2023; 13:1083. [PMID: 37887408 PMCID: PMC10608860 DOI: 10.3390/metabo13101083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 09/30/2023] [Accepted: 10/09/2023] [Indexed: 10/28/2023] Open
Abstract
Recent studies have reported several beneficial effects of natural compounds on cancerous cells, highlighting their use for future treatments. These preliminary findings have encouraged experiments with natural substances, such as plant extracts, to examine both cytotoxic and mitogenic effects and find alternative treatments for diseases such as breast cancer. This study examines the effects of microwave-assisted and ethanol maceration of marjoram (Origanum majorana) on MCF-7 breast cancer cell lines and normal breast tissue cell lines used as controls. Marjoram extracts displayed a cytotoxic effect on the MCF-7 cell lines and a mitogenic effect on the control cell lines at the MTS test. The metabolic profiles of MCF-7 and control cell lines were also assessed using the Biolog Phenotype Mammalian Metabolic (PM-M) platform and revealed statistically significant differences in the utilization of energy sources, metabolic activity in the presence of certain ionic species, and responses to metabolic effectors, such as stimulant/catabolic compounds and steroid hormones. Exposure to marjoram extracts exerted positive effects on the MCF-7 cells on the abnormal utilization of energy sources and the responses to metabolic effectors, while no major effects were detected on control cells. These effects were compared to the metabolic impact of the chemotherapeutic agent doxorubicin, which showed profound cytotoxic effects on both cancerous and normal breast cells. In conclusion, our in vitro evidence indicates that marjoram extracts are a promising alternative to chemotherapy in breast cancer since they can successfully eliminate cancerous cells by affecting their metabolic capacity to proliferate without inducing noticeable adverse effects on normal breast tissue.
Collapse
Affiliation(s)
- Zoe Sanders
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - Bridgette A. Moffitt
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
| | - Madeleine Treaster
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - Ashley Larkins
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
| | - Nicholas Khulordava
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
| | - Jennifer Benjock
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
| | - Jillian Spencer
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
| | - Krista Henrie
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
| | - Matthew J. Wurst
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - Abigail Broom
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - Noah Tamez
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - Gianna DeRosa
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - McKenzie Campbell
- Department of Chemistry, Anderson University, Anderson, SC 29621, USA
| | - Elizabeth Keller
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - Addison Powell
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
| | - Donna Weinbrenner
- Department of Biological Sciences, Clemson University, Clemson, SC 29634, USA
| | - Ludovico Abenavoli
- Department of Health Sciences, University “Magna Graecia”, Viale Europa—Germaneto, 88100 Catanzaro, Italy;
| | | | - Ki Chung
- Prisma Health Cancer Institute, Greenville, SC 29605, USA (K.C.)
| | - Luigi Boccuto
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
| | - Diana Ivankovic
- Departments of Biology, Center for Cancer Research, Anderson University, 316 Boulevard, Anderson, SC 29621, USA; (Z.S.); (A.B.); (A.P.)
- Department of Healthcare Genetics, School of Nursing, Clemson University, Clemson, SC 29634, USA (J.S.); (L.B.)
- Department of Biological Sciences, Anderson University, 316 Boulevard, Anderson, SC 29621, USA
| |
Collapse
|
2
|
Funkhouser A, Shuster H, Martin JC, Edenfield WJ, Blenda AV. Pattern Analysis of Serum Galectins-1, -3, and -9 in Breast Cancer. Cancers (Basel) 2023; 15:3809. [PMID: 37568625 PMCID: PMC10417135 DOI: 10.3390/cancers15153809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 07/24/2023] [Accepted: 07/25/2023] [Indexed: 08/13/2023] Open
Abstract
Galectins have been shown to have roles in cancer progression via their contributions to angiogenesis, metastasis, cell division, and the evasion of immune destruction. This study analyzes galectin-1, -3, and -9 serum concentrations in breast cancer patients through enzyme-linked immunosorbent assay (ELISA) against the characteristics of the patient and the tumor such as stage, molecular subtype, and receptor expression. Galectin-9 was found to be statistically significantly increased in HER2-enriched tumors and reduced in patients with hormone-receptor-positive tumors. Galectin-1 was found to be statistically significantly increased in the serum of patients who had undergone hormonal, immunotherapy, or chemotherapy. These findings provide insight into the changes in galectin levels during the progress of cancer, the response to treatment, and the molecular phenotype. These findings are valuable in the further understanding of the relationships between galectin and tumor biology and can inform future research on therapeutic targets for galectin inhibitors and the utility of galectin biomarkers.
Collapse
Affiliation(s)
- Avery Funkhouser
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA
| | - Hayden Shuster
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA
| | - Julie C. Martin
- Prisma Health Cancer Institute, Prisma Health, Greenville, SC 29605, USA
| | - W. Jeffery Edenfield
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA
- Prisma Health Cancer Institute, Prisma Health, Greenville, SC 29605, USA
| | - Anna V. Blenda
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA
- Prisma Health Cancer Institute, Prisma Health, Greenville, SC 29605, USA
| |
Collapse
|
3
|
Firooz A, Funkhouser AT, Martin JC, Edenfield WJ, Valafar H, Blenda AV. Abstract 5425: Analysis of cancer patients’ molecular and clinical data using artificial intelligence and machine learning approaches. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-5425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Background: Development and clinical course of cancer is multifactorial with influences from the general health status of the patient, germline and neoplastic mutations, co-morbidities, and environment including lifestyle. For effective and individualized treatment of each patient, such multifactorial data must be easy-to-access and easy-to-analyze.
Purpose Statement: Cancers are characterized on a molecular level by the presence of complex gene mutations and other specific molecular markers. Moreover, special importance is placed on so-called cancer-critical genes, mutations of which are involved in the development and progression of various cancers. However, not all detected sequence alterations in these genes are known as cancer-causing mutations; thus, a more detailed and sensitive analysis is prudent. In addition, there is a limited number of established and reliable cancer biomarkers of sera. To that end, a complete analysis of molecular basis of cancer needs to include additional biomarkers such as galectins and glycans, since patients’ galectin and glycomic profiles have promising cancer differentiating and diagnostic potential.
Methods: We utilized a Relational Database Management System populated by clinical data from the Prisma Health Cancer Institute Biorepository of ~6,000 cancer patients with at least 66 different cancer diagnoses. Molecular data is available for gene mutations, serum galectin proteins, and glycomic profiles of cancer patients. Mutation status of 50 cancer-critical genes in 1,500 patients, 320 individual patient profiles of 5 serum galectin proteins, and serum and tissue glycomic profiles of 60 patients have been included and will be expanded. In addition, healthy control values for galectin and glycomic profiles were obtained and added for reference. We performed statistical and AI models of Data Analytics using R, Python, and TensorFlow platforms. A comprehensive set of patient data was used to develop a predictive model of patient outcome using the clinical observations as the desired outcome.
Results: The use of typical statistical analyses (linear and logistic regression) revealed insignificant correlation between the predictors and the cancer type of patient outcome. However, the use of the Decision Tree revealed some interesting relationships that can be used for explainability and reliability of the Machine Learning approaches. Finally, Artificial Neural Network approaches provided the best performance in classification of cancer types from the given information.
Conclusion: Our studies provide predictive models that could potentially be used to improve the diagnostic and prognostic power of data collected from patients at presentation. However, the dichotomy of black box AI approaches that perform better than explainable approaches, complicate deployment of these techniques in the domain of medicine and healthcare.
Citation Format: Ali Firooz, Avery T. Funkhouser, Julie C. Martin, W. Jeffery Edenfield, Homayoun Valafar, Anna V. Blenda. Analysis of cancer patients’ molecular and clinical data using artificial intelligence and machine learning approaches. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5425.
Collapse
Affiliation(s)
- Ali Firooz
- 1University of South Carolina, Columbia, SC
| | | | | | | | | | - Anna V. Blenda
- 2University of South Carolina School of Medicine Greenville, Greenville, SC
| |
Collapse
|
4
|
Firooz A, Funkhouser AT, Martin JC, Edenfield WJ, Valafar H, Blenda AV. Comprehensive and User-Analytics-Friendly Cancer Patient Database for Physicians and Researchers. ArXiv 2023:arXiv:2302.01337v1. [PMID: 36776819 PMCID: PMC9915752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
Nuanced cancer patient care is needed, as the development and clinical course of cancer is multifactorial with influences from the general health status of the patient, germline and neoplastic mutations, co-morbidities, and environment. To effectively tailor an individualized treatment to each patient, such multifactorial data must be presented to providers in an easy-to-access and easy-to-analyze fashion. To address the need, a relational database has been developed integrating status of cancer-critical gene mutations, serum galectin profiles, serum and tumor glycomic profiles, with clinical, demographic, and lifestyle data points of individual cancer patients. The database, as a backend, provides physicians and researchers with a single, easily accessible repository of cancer profiling data to aid-in and enhance individualized treatment. Our interactive database allows care providers to amalgamate cohorts from these groups to find correlations between different data types with the possibility of finding "molecular signatures" based upon a combination of genetic mutations, galectin serum levels, glycan compositions, and patient clinical data and lifestyle choices. Our project provides a framework for an integrated, interactive, and growing database to analyze molecular and clinical patterns across cancer stages and subtypes and provides opportunities for increased diagnostic and prognostic power.
Collapse
Affiliation(s)
- Ali Firooz
- College of Engineering and Computing, University of South Carolina, Columbia, SC, USA
| | - Avery T Funkhouser
- School of Medicine Greenville, University of South Carolina, Greenville, SC, USA
| | | | | | - Homayoun Valafar
- College of Engineering and Computing, University of South Carolina, Columbia, SC, USA
| | - Anna V Blenda
- School of Medicine Greenville, University of South Carolina, Prisma Health Cancer Institute, Greenville, SC, USA
| |
Collapse
|
5
|
Chaballout BH, Funkhouser AT, Blair BB, Goodwin JL, Strigenz AM, Arthur CM, Martin JC, Edenfield WJ, Blenda AV. Abstract 5028: Integration of molecular data into cancer patient database. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-5028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Precision medicine holds promise of being a more effective method for treating complex diseases such as cancer. Nuanced care is needed, as the development and clinical course of cancer is multifactorial with influences from the general health status of the patient, germline and neoplastic mutations, co-morbidities, and environment including "lifestyle". To tailor an individualized treatment to the patient, such multifactorial data must be presented in an easy-to-use, easy-to-analyze fashion for providers to use effectively.
Purpose: To address the need, we have built a searchable database integrating cancer-critical gene mutation status, serum galectin protein markers, serum and tumor glycomic profiles, with clinical, demographic, and lifestyle data points of individual patients.
Methods: The initial data was acquired from breast, colon, and lung cancer patients’ serum and biopsy samples from the Prisma Health Cancer Institute Biorepository. The acquired data contains the status of 2,800 COSMIC cancer-critical gene mutations, individual patient profiles of five serum galectins, and serum and biopsy glycan structures from each patient’s glycomic profile. DNA from tumor cells was used to screen the regions frequently mutated in human cancer genes. Multiplex PCR using Ion AmpliSeq࣪ Cancer Hotspot panel v2 was performed by Precision Genetics. Enzyme-linked immunosorbent assay was employed to perform galectin profiling of cancer patient serum samples. Glycomic profiling of serum and biopsy samples was performed by the Emory Comprehensive Glycomic Core. In addition, healthy control values for galectin and glycomic profiles were obtained and added to the patient database for reference. The data is being stored using Microsoft SQL servers and is fed into an interactive web application using RStudio.
Results: Our interactive database allows care providers to amalgamate cohorts from these groups to find correlations between different data types with the possibility of finding a "stage signature" based upon a combination of genetic mutations, galectin serum levels, glycan signatures, and patient clinical data and lifestyle choices.
Conclusion: Our project provides a framework for an integrated interactive database to analyze molecular and clinical patterns across cancer stages and provides opportunities for increased diagnostic and prognostic power.
Citation Format: Basil H. Chaballout, Avery T. Funkhouser, Bailey B. Blair, Jane L. Goodwin, Alexander M. Strigenz, Connie M. Arthur, Julie C. Martin, W. Jeffery Edenfield, Anna V. Blenda. Integration of molecular data into cancer patient database [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5028.
Collapse
Affiliation(s)
| | | | - Bailey B. Blair
- 1University of South Carolina School of Medicine Greenville, Greenville, SC
| | - Jane L. Goodwin
- 1University of South Carolina School of Medicine Greenville, Greenville, SC
| | | | - Connie M. Arthur
- 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
| | | | | | - Anna V. Blenda
- 1University of South Carolina School of Medicine Greenville, Greenville, SC
| |
Collapse
|
6
|
Funkhouser A, Chaballout B, Goodwin J, Martin J, Edenfield WJ, Arthur CM, Blenda AV. Comprehensive Glycomic Profiling of Breast Cancer Patients. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r5081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Avery Funkhouser
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| | - Basil Chaballout
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| | - Jane Goodwin
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| | - Julie Martin
- Prisma Health Cancer InstitutePrisma HealthGreenvilleSC
| | | | | | - Anna V. Blenda
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
- Prisma Health Cancer InstituteUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| |
Collapse
|
7
|
Funkhouser A, Blair B, Goodwin J, Strigenz A, Martin J, Funk CR, Edenfield WJ, Blenda AV. Non‐coding
FLT3
Mutation is Associated with Lower Galectin Levels in Breast Cancer Patients. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r5238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Avery Funkhouser
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| | - Bailey Blair
- Biomedical ScienceUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| | - Jane Goodwin
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| | - Alec Strigenz
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| | - Julie Martin
- Prisma Health Cancer InstitutePrisma HealthGreenvilleSC
| | | | | | - Anna V. Blenda
- Biomedical SciencesUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
- Prisma Health Cancer InstituteUniversity of South Carolina School of Medicine GreenvilleGreenvilleSC
| |
Collapse
|
8
|
Blair BB, Funkhouser AT, Goodwin JL, Strigenz AM, Chaballout BH, Martin JC, Arthur CM, Funk CR, Edenfield WJ, Blenda AV. Increased Circulating Levels of Galectin Proteins in Patients with Breast, Colon, and Lung Cancer. Cancers (Basel) 2021; 13:cancers13194819. [PMID: 34638303 PMCID: PMC8508020 DOI: 10.3390/cancers13194819] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 09/12/2021] [Accepted: 09/22/2021] [Indexed: 12/20/2022] Open
Abstract
Galectins are proteins with high-affinity β-galactoside-binding sites that function in a variety of signaling pathways through interactions with glycoproteins. The known contributions of galectins-1, -3, -7, -8, and -9 to angiogenesis, metastasis, cell division, and evasion of immune destruction led us to investigate the circulating levels of these galectins in cancer patients. This study compares galectin concentrations by enzyme-linked immunosorbent assay (ELISA) from each stage of breast, lung, and colon cancer. Galectins-1 and -7, which share a prototype structure, were found to have statistically significant increases in breast and lung cancer. Of the tandem-repeat galectins, galectin-8 showed no statistically significant change in these cancer types, but galectin-9 was increased in colon and lung cancer. Galectin-3 is the only chimera-type galectin and was increased in all stages of breast, colon, and lung cancer. In conclusion, there were significant differences in the galectin levels in patients with these cancers compared with healthy controls, and galectin levels did not significantly change from stage to stage. These findings suggest that further research on the roles of galectins early in disease pathogenesis may lead to novel indications for galectin inhibitors.
Collapse
Affiliation(s)
- Bailey B. Blair
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; (B.B.B.); (A.T.F.); (J.L.G.); (A.M.S.); (B.H.C.)
| | - Avery T. Funkhouser
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; (B.B.B.); (A.T.F.); (J.L.G.); (A.M.S.); (B.H.C.)
| | - Jane L. Goodwin
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; (B.B.B.); (A.T.F.); (J.L.G.); (A.M.S.); (B.H.C.)
| | - Alexander M. Strigenz
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; (B.B.B.); (A.T.F.); (J.L.G.); (A.M.S.); (B.H.C.)
| | - Basil H. Chaballout
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; (B.B.B.); (A.T.F.); (J.L.G.); (A.M.S.); (B.H.C.)
| | - Julie C. Martin
- Prisma Health Cancer Institute, Greenville, SC 29605, USA; (J.C.M.); (W.J.E.)
| | - Connie M. Arthur
- Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA;
| | - Christopher Ronald Funk
- Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA;
| | | | - Anna V. Blenda
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA; (B.B.B.); (A.T.F.); (J.L.G.); (A.M.S.); (B.H.C.)
- Prisma Health Cancer Institute, Greenville, SC 29605, USA; (J.C.M.); (W.J.E.)
- Correspondence:
| |
Collapse
|
9
|
Gluck WL, Callahan SP, Brevetta RA, Stenbit AE, Smith WM, Martin JC, Blenda AV, Arce S, Edenfield WJ. Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19. Respir Med 2020; 175:106188. [PMID: 33190086 PMCID: PMC7648522 DOI: 10.1016/j.rmed.2020.106188] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 10/05/2020] [Accepted: 10/06/2020] [Indexed: 01/06/2023]
Abstract
Objectives Cytokine release syndrome (CRS) is a potentially severe complication of COVID-19 most commonly resulting in respiratory failure. This ten-patient study was designed to determine the efficacy of therapeutic plasma exchange (TPE) in improving oxygenation and in reducing the cytokine load in a critically ill subset of patients. Methods Five single volume plasma exchanges over eight days within a 14-day study period. In mechanically ventilated patients, oxygenation was measured via the PaO2/FiO2 (P/F) ratio and the oxygenation index (OI) daily for 14 days. Supplemental oxygen requirements were tracked daily for non-ventilated patients. Results Non-ventilated patients were liberated from supplemental oxygen after TPE. The response was rapid with an 87% average reduction in oxygenation requirements following and average time to return to room air of 5.25 days. All mechanically ventilated patients demonstrated improvement in oxygenation with a 78% average improvement in the P/F ratio and a 43% improvement in OI. C-reactive protein (CRP) and serum levels of IL-6, IL-8, IL-10, TNFα, IFNγ and GM-CSF, were measured daily with immediate post TPE levels drawn on days 1, 2, 4, 6 and 8. All patients demonstrated significant reductions in CRP, IL-6, IL-10 and TNFα. Conclusions In the majority of patients with Penn class 3 and 4 CRS complicating COVID-19, TPE demonstrated a prompt improvement in oxygenation and reduction in cytokine load without compromising patient safety. As this pilot study was envisioned to be hypothesis generating, expanded trials using TPE alone and in conjunction with novel pharmacologic agents are warranted. Registration ClinicalTrials.gov NCT04374149. Plasmapheresis can effectively reduce injurious cytokines that complicate COVID-19. Plasmapheresis can produce clinically meaningful improvement in oxygenation. Plasmapheresis can be safely used as a treatment for COVID-19 cytokine storm.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Anna V Blenda
- University of South Carolina School of Medicine Greenville, SC, USA
| | - Sergio Arce
- University of South Carolina School of Medicine Greenville, SC, USA
| | | |
Collapse
|
10
|
Hamilton EP, Barve M, Bardia A, Beeram M, Edenfield WJ, Noonan A, Tolcher A, Bendell J, Mosher R, Xu J, Hailman E, Burris III H, Soliman HH. Abstract P6-17-35: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-17-35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Hamilton EP, Barve M, Bardia A, Beeram M, Edenfield WJ, Noonan A, Tolcher A, Bendell J, Mosher R, Xu J, Hailman E, Burris III H, Soliman HH. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-35.
Collapse
Affiliation(s)
- EP Hamilton
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - M Barve
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - A Bardia
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - M Beeram
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - WJ Edenfield
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - A Noonan
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - A Tolcher
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - J Bendell
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - R Mosher
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - J Xu
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - E Hailman
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - H Burris III
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| | - HH Soliman
- Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Texas Oncology, Dallas, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; START, San Antonio, TX; Institute for Translational Oncology Research, Greenville, SC; The Ohio State University Comprehensive Cancer Center, Columbus, OH; Next Oncology, San Antonio, TX; Mersana Therapeutics, Cambridge, MA; Moffitt Cancer Center, Tampa, FL
| |
Collapse
|
11
|
Garcia-Manero G, Gore SD, Kambhampati S, Scott B, Tefferi A, Cogle CR, Edenfield WJ, Hetzer J, Kumar K, Laille E, Shi T, MacBeth KJ, Skikne B. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia 2015; 30:889-96. [PMID: 26442612 PMCID: PMC4832070 DOI: 10.1038/leu.2015.265] [Citation(s) in RCA: 86] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Revised: 09/02/2015] [Accepted: 09/16/2015] [Indexed: 11/18/2022]
Abstract
CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical development for treatment of hematologic malignancies. CC-486 administered for 7 days per 28-day treatment cycle was evaluated in a phase 1 dose-finding study. AZA has a short plasma half-life and DNA incorporation is S-phase-restricted; extending CC-486 exposure may increase the number of AZA-affected diseased target cells and maximize therapeutic effects. Patients with lower-risk myelodysplastic syndromes (MDS) received 300 mg CC-486 once daily for 14 days (n=28) or 21 days (n=27) of repeated 28-day cycles. Median patient age was 72 years (range 31–87) and 75% of patients had International Prognostic Scoring System Intermediate-1 risk MDS. Median number of CC-486 treatment cycles was 7 (range 2–24) for the 14-day dosing schedule and 6 (1–24) for the 21-day schedule. Overall response (complete or partial remission, red blood cell (RBC) or platelet transfusion independence (TI), or hematologic improvement) (International Working Group 2006) was attained by 36% of patients receiving 14-day dosing and 41% receiving 21-day dosing. RBC TI rates were similar with both dosing schedules (31% and 38%, respectively). CC-486 was generally well-tolerated. Extended dosing schedules of oral CC-486 may provide effective long-term treatment for patients with lower-risk MDS.
Collapse
Affiliation(s)
- G Garcia-Manero
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - S D Gore
- Yale Cancer Center, New Haven, CT, USA
| | - S Kambhampati
- Division of Hematology/Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
| | - B Scott
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - A Tefferi
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - C R Cogle
- Medicine/Hematology & Oncology, University of Florida, Gainesville, FL, USA
| | - W J Edenfield
- Cancer Centers of The Carolinas, Greenville, SC, USA
| | - J Hetzer
- Celgene Corporation, Summit, NJ, USA
| | - K Kumar
- Celgene Corporation, Summit, NJ, USA
| | - E Laille
- Celgene Corporation, Summit, NJ, USA
| | - T Shi
- Celgene Corporation, Summit, NJ, USA
| | | | - B Skikne
- Celgene Corporation, Summit, NJ, USA
| |
Collapse
|
12
|
Edenfield WJ, Moores LK, Goodwin G, Lee N. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant 2000; 25:405-9. [PMID: 10723584 DOI: 10.1038/sj.bmt.1702155] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Engraftment syndrome (ES) is a toxicity of autologous stem cell transplantation that occurs unexpectedly and is occasionally fatal. This syndrome, manifested as fever, rash and pulmonary deterioration which becomes evident at marrow engraftment, has been described by several centers but as yet remains enigmatic. We describe this syndrome at a single institution and note that it has accompanied the transition from the use of autologous marrow rescue to peripheral blood stem cell rescue. In this study, the occurrence of ES is related to the mononuclear cell dose at reinfusion. We found, in agreement with other reports, that patients developing ES are predominantly women undergoing therapy for solid tumors who demonstrate neutrophil engraftment at a significantly greater rate than do those patients not expressing the syndrome. We did not note a significant relationship between growth factor use (G-CSF) or amphotericin B exposure and the syndrome, as has been previously reported. The progenitor cell populations obtained with autologous marrow and peripheral blood stem cells are different. We hypothesize that the interaction of committed myeloid precursors from the stem cell product with the pulmonary vascular endothelium can be deleterious, especially under the influence of the inflammatory cytokines present at the time of engraftment.
Collapse
Affiliation(s)
- W J Edenfield
- Department of Medicine, Hematology/Oncology, Walter Reed Army Medical Center, Washington, DC, USA
| | | | | | | |
Collapse
|
13
|
Shorr AF, Moores LK, Edenfield WJ, Christie RJ, Fitzpatrick TM. Mechanical ventilation in hematopoietic stem cell transplantation: can We effectively predict outcomes? Chest 1999; 116:1012-8. [PMID: 10531167 DOI: 10.1378/chest.116.4.1012] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Survival rates from mechanical ventilation (MV) in allogeneic bone marrow transplantation are poor, but little is known about the need for and outcomes from MV in patients who undergo autologous hematopoietic stem cell transplantation (AHSCT). STUDY OBJECTIVE To determine the frequency of and risk factors for the use of MV in recipients of AHSCT and to identify predictors of survival in mechanically ventilated AHSCT patients. DESIGN Retrospective, cohort analysis SETTING Tertiary-care, university-affiliated medical center. PATIENTS One hundred fifty-nine consecutive patients who underwent AHSCT. INTERVENTIONS Patient surveillance and data collection. MEASUREMENTS AND RESULTS The primary outcome measure was the need for MV, and the secondary end point was survival after MV. Of 159 patients, 17 required MV (10. 7%). Three variables were associated with the need for MV: increasing age, use of total body irradiation in the conditioning regimen, and treatment with amphotericin B. As a screening test to predict the need for MV, no risk factor had a sensitivity or specificity > 82%. Three of the 17 mechanically ventilated patients (17.6%) survived to discharge. Only the mean APACHE (acute physiology and chronic health evaluation) II score separated survivors from nonsurvivors (21.7 vs 31.4; p = 0.029). Both the duration of MV and the length of stay in the ICU were similar in survivors and nonsurvivors. CONCLUSIONS We conclude that MV is infrequently needed following AHSCT. Although survival after MV in these patients is limited, clinical variables do not reliably allow clinicians to prospectively identify patients destined to die.
Collapse
Affiliation(s)
- A F Shorr
- Division of Pulmonary & Critical Care Medicine, Walter Reed Army Medical Center, Washington, DC 20307, USA.
| | | | | | | | | |
Collapse
|
14
|
Edenfield WJ, Gore SD. Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia. Semin Oncol 1999; 26:21-34. [PMID: 10073559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Allogeneic (alloBMT) and autologous bone marrow transplantation (ABMT) have become standard approaches for the management of adults with acute myeloid leukemia (AML). The indications for transplantation remain controversial as parallel improvements in intensive chemotherapy have resulted in excellent outcomes for many patients. AlloBMT is the therapy of choice for patients who fail to respond to induction chemotherapy. For those patients in first remission (CRI), a policy of intensive postremission chemotherapy with transplantation upon relapse appears to be optimal. There are no data to support transplantation in CRI, allogeneic or autologous, for those patients with leukemia characterized by favorable cytogenetic abnormalities [ie, core-binding factor type or t(15;17)], as these patients do well with nonmyeloablative strategies. Patients with relapsed disease appear to be best served with allogeneic transplantation from a human leukocyte antigen (HLA)-matched sibling or one-antigen-mismatched family member, whereas for those patients lacking a related donor, unrelated donor alloBMT or ABMT provides similar long-term overall survival. Randomized studies for the optimal management of relapsed disease are lacking but are needed. The objective of this review is to discuss the data supporting the use of alloBMT or ABMT at various points during the course of de novo adult AML.
Collapse
Affiliation(s)
- W J Edenfield
- Hematology/Oncology Service, Walter Reed Army Medical Center, Washington, DC, USA
| | | |
Collapse
|
15
|
Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 1999; 17:293-7. [PMID: 10458245 DOI: 10.1200/jco.1999.17.1.293] [Citation(s) in RCA: 98] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Blast expression of CD56 is frequent in patients with t(8;21)(q22;q22) acute myeloid leukemia and is associated with an inferior outcome. The expression of CD56 has rarely been reported in acute promyelocytic leukemia (APL) and has not been clinically characterized. Therefore, we examined the prognostic significance of CD56 expression in APL. PATIENTS AND METHODS We identified all reported cases of CD56+ APL in the medical literature and collected clinical, biologic, and therapeutic details. RESULTS Data were obtained for 12 patients with CD56+ APL (> 20% blast expression of CD56), including four cases from a single institution with a total of 42 APL patients. All of the CD56+ APL patients had documented cytogenetic presence of t(15;17), and of the nine reported isotypes, eight (89%) were S-isoform. Only six CD56+ patients (50%) attained complete remission (CR); the other six individuals died within 35 days of presentation. Of the six patients who attained a CR, three (50%) relapsed at 111, 121, and 155 weeks, whereas three remained in continuous CR at 19, 90, and 109 weeks. Comparison of the control CD56- to CD56+ APL patients demonstrated that the latter group had a significantly lower fibrinogen level (P = .007), and among patients for whom data were available, there was a higher frequency of the S-isoform (P = .006). Additionally, the CR rate (50% v 84%, P = .025) and overall median survival (5 v 232 weeks; P = .019) were significantly inferior for CD56+ APL patients. CONCLUSION CD56+ acute promyelocytic leukemia is infrequent, seems to occur more frequently with the S-isoform subtype, and may be associated with a lower CR rate and inferior overall survival.
Collapse
Affiliation(s)
- C K Murray
- Walter Reed Army Medical Center, Washington, DC 20307, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Byrd JC, Edenfield WJ, Dow NS, Aylesworth C, Dawson N. Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia. Leuk Lymphoma 1996; 21:153-9. [PMID: 8907283 DOI: 10.3109/10428199609067593] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The purpose of this report is to record a patient with myelodysplastic syndrome (MDS) associated acute myelogenous leukemia (AML) and leukemia cutis who had blast expression of the neural cell adhesion molecule (NCAM) and to review the world literature on prognostic implications of extramedullary myeloid cell tumors (granulocytic sarcoma, myeloblastoma, chloroma and leukemia cutis) in MDS and MDS associated AML. Case report and world literature from January 1965-January 1994 for all cases of MDS-associated extramedullary myeloid cell tumors (EMT) is reviewed, and the first patient with EMT, MDS associated AML and blast expression of NCAM is described. There have been 46 cases of MDS associated EMT previously reported. 32 cases occurred in the absence of AML. AML developed in 47% of these patients at a mean of 38 weeks from initial EMT. Of the patients not developing AML, median survival from initial EMT was 11 weeks. Nine patients received chemotherapy at the time of EMT and had a median survival of 36 weeks. The median survival for patients receiving conservative therapy for EMT was 48 weeks. Patients (n = 15) with EMT and MDS associated AML had a poor outcome regardless of therapy with a median survival of 11 weeks. Unlike other forms of isolated EMT, MDS associated EMT is not always a forerunner of AML. Premature induction therapy for MDS associated EMT does not appear to prolong survival. EMT in the setting of MDS associated AML is associated with a poor prognosis despite aggressive chemotherapy. Blast expression of NCAM may prove to be a risk factor for EMT in MDS associated AML.
Collapse
Affiliation(s)
- J C Byrd
- Division of Hematology-Oncology, Department of Internal Medicine, Walter Reed Army Medical Center and the Uniformed Services University of the Health Sciences, Washington, DC 20307, USA
| | | | | | | | | |
Collapse
|
17
|
Mammen MP, Aronson NE, Edenfield WJ, Endy TP. Recurrent Helicobacter cinaedi bacteremia in a patient infected with human immunodeficiency virus: case report. Clin Infect Dis 1995; 21:1055. [PMID: 8645814 DOI: 10.1093/clinids/21.4.1055] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Affiliation(s)
- M P Mammen
- Department of Medicine, Walter Reed Army Medical Center, Washington, D.C. 20307, USA
| | | | | | | |
Collapse
|
18
|
Abstract
PURPOSE To discuss the predisposing risk factor for all forms of extramedullary leukemia (EML) and to review the clinical features, prognostic significance, and treatment strategies for primary EML and leukemia cutis (LC)/granulocytic sarcomas (GS) in the setting of acute nonlymphocytic leukemia (ANLL). METHODS A review of all reports published since 1965 related to all forms of extramedullary leukemia (LC, GS, gingival hypertrophy, and meningeal leukemia [ML]). RESULTS Several factors, including chromosomal abnormalities [t(8;21), inv(16)], cell-surface markers (CD56, CD2, CD4, CD7), French-American-British (FAB) subtype (M2, M4, M5), blast differentiation and maturation, patient nutritional status, age, cellular immune dysfunction, high presenting leukocyte count, and decreased blast Auer rods, have been associated with a higher incidence of EML. Of 154 published cases of primary EML identified, 71 (46%) were initially misdiagnosed. The addition of immunohistochemical stains can assist in preventing such misdiagnoses and should be included in all atypical lymphoma/carcinoma cases. Only one of the patients (3%) with primary EML did not progress to ANLL in the absence of chemotherapy. In contrast, 66% of patients who received chemotherapy for the primary EML never developed ANLL. The prognostic significance of EML at presentation and medullary relapse of ANLL is uncertain. Isolated extramedullary recurrence of ANLL always heralds bone marrow relapse and should be treated with reinduction chemotherapy. Close clinical follow-up observation is necessary to insure resolution of EML. Radiation therapy is an effective local treatment for resistant or symptomatic EML. CONCLUSION Many advances in diagnoses and treatment of EML have been made. Future investigations are needed to define the clinical significance of EML in patients with ANLL treated with modern chemotherapy or bone marrow transplantation.
Collapse
MESH Headings
- Age Factors
- Biomarkers
- Follow-Up Studies
- Humans
- Incidence
- Leukemia, Myeloid/pathology
- Leukemia, Myeloid, Acute/diagnostic imaging
- Leukemia, Myeloid, Acute/epidemiology
- Leukemia, Myeloid, Acute/etiology
- Leukemia, Myeloid, Acute/pathology
- Leukemia, Myeloid, Acute/therapy
- Radiography
- Risk Factors
Collapse
Affiliation(s)
- J C Byrd
- Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307, USA
| | | | | | | |
Collapse
|